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Introduction   
   
A biomarker is a substance used to indicate a biologic state. It can be defined 
as, ―A substance that is measured objectively and evaluated as an indicator of normal 
biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention
1
.‖
 
Traditional biomarkers in medicine include heart rate, blood 
pressure, imaging (X-rays), and the prostate-specific screening antigen test (PSA) for 
prostate cancer. 
 
As periodontitis is considered to be a multifactorial disease with no clear cut 
etiology, so its identification and early diagnosis becomes all the more difficult and 
important. So with the current objective the need for periodontal diagnostic tool 
which would provide adequate information for differential diagnosis, localization of 
disease, and severity of infection arises all the more. These diagnostics should not only 
aim at mere diagnosis of the underlying disease but should also serve as a basis for 
planning treatment and provide the means for assessing the effectiveness of 
periodontal therapy. Ironically, the current clinical diagnostic parameters that were 
introduced more than 50 years ago continue to function as the basic model for 
periodontal diagnosis in clinical practice today. These include probing pocket depths, 
bleeding on probing, clinical attachment levels, plaque index, and radiographs that 
quantify alveolar bone levels
5
 these traditional biomarkers were attributed with ease of 
use, cost-effectiveness, and relatively non-invasive. 
 
A traditional biomarker for periodontal disease is bleeding on probing (BOP), 
supposedly the best disease predictor available today (Fig.1). According to Researchers 
there are many false positives associated with it, but the absence of BOP is considered 
a very precise negative predictor of disease activity
5
, periodontal diagnosis is based 
upon subjective clinical examination procedures that may be time-consuming and 
poorly implemented by the operator. Many a time diagnosis is solely based upon 
periodontal probing measurements due to time constraints, which lead to under 
diagnosis & inappropriate treatment and low rates of appropriate therapeutic 
intervention. 
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Abstract      
                         
The ability to monitor health status, disease onset and progression, and treatment outcome 
through non-invasive means is a most desirable goal in health-care promotion and delivery. 
There are certain ground rules for this goal to be realized: specific biomarkers associated with 
a health or disease state, a non-invasive approach to detect and monitor the biomarkers,  and 
the technologies to discriminate between and among the biomarkers. We in the present 
literature have tried to assess a pathway to achieve these goals using oral fluids as the 
diagnostic medium to analyse the health and/or disease status of individuals . As the "mirror of 
body", oral fluid is a perfect medium to explore regarding health and disease regulation.  
 
KEYWORDS:  Biomarkers, non-invasive, diagnostic. 
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periodontal probing measurements due to time 
constraints, which lead to under diagnosis & 
inappropriate treatment and low rates of appropriate 
therapeutic intervention. 
 
Dilemmas in decision making and the way out:- 
 How can clinicians assess risk for 
periodontal disease? 
 What are the useful laboratory and 
clinical methods for periodontal risk 
assessment? 
 What can be achieved by controlling 
periodontal disease using a risk profile? 
 
Risk factors are considered modifiers of disease activity. 
In association with host susceptibility and a variety of 
local and systemic conditions, they influence the 
initiation and progression of periodontitis and successive 
changes on biomarkers. Therefore, additional diagnostic 
and prognostic tests have been extensively sought to 
address these problems. Thus advances in oral and 
periodontal disease diagnostic research are moving 
toward methods whereby periodontal risk can be 
identified and quantified by objective measures such as 
biomarkers. 
 Diagnostic tools to measure periodontal disease 
at the molecular, cellular, tissue, and clinical levels
2
 are: 
At molecular level activation of receptors for endotoxin: 
CD-14, toll like receptors occurs which can be diagnosed 
by PCR, DNA hybridization etc. 
Similarly at tissue & cellular level; ELISA, 
Immunohistochemistry can be used. At clinical level 
periodontal probing, radiographs have always been 
there. 
Chronic periodontitis is now considered a site-
specific disease, but what has continued to puzzle 
periodontal researchers is the unpredictability of the 
disease at a patient and site-level. As a result, a flurry of 
research activity was underway in the 1990s to study the 
utility and value of individual biomarkers of periodontal 
disease activity. Researchers such as Chapple
3
 thus 
created biomarkers that indicated the presence or 
absence of periodontal pathogens, gingival and 
periodontal inflammation, the host inflammatory-
immune response to certain pathogenic species, and 
host tissue destruction. The biological media of choice 
included saliva, serum, subgingival plaque, tissue 
biopsies, and gingival crevicular fluid. As a result, and 
after many biomarkers and diagnostic tests were 
developed, a number of diagnostic kits became 
available. These kits included biomarkers within gingival 
crevicular fluid, but market research wasn't performed 
and the kits failed to reach the practice community. 
Chapple
3
 reported problems as they were not user 
friendly, costly, time consuming, & complex to perform 
& understand. 
Saliva was then looked at as another choice for an 
appropriate diagnostic medium. The challenges are 
enormous, because it still isn't known what the exact 
phenomena are that trigger the cascade of events 
leading to tissue destruction, and a biomarker needs to 
predict disease onset and progression. It's possible that 
the markers associated with inflammation are not the 
ones responsible for initiating the disease process. It's 
also possible that markers that characterize the 
inflammatory process in gingivitis are different from 
those that develop in periodontitis. 
A biomarker is an objective measure that can be 
evaluated and confirmed and not only any particular 
substance as was stated in definition. Oral fluid 
biomarkers that have been studied for periodontal 
diagnosis include proteins of host origin (e.g. 
immunoglobulins), phenotypic markers, host cells (e.g., 
PMNs), hormones, bacteria and bacterial products, ions, 
and volatile compounds. Since periodontitis is a 
multifactorial disease that includes initiation by bacteria 
and host interaction, it's unlikely that a single biomarker 
will be able to predict periodontal disease activity. So 
combinations could be tried. 
 
CURRENT TRENDS: 
Recent advances in the use of biomarker based 
diagnostics for disease activity include mediators that 
are released into GCF & saliva can be broadly grouped 
according to their sources as grouped as
2,4 
1) Microbial plaque: Endotoxins 
(lipopolysachrides), Enzymes, Metabolic end 
products, DNA probes, Cultures of putative 
periodontal pathogens. 
2) Host derived :- 1L-β, Aspartate, 
Aminotransferase, Transferase, Matrix proteins, 
Lactoferrin, Lysozyme etc… 
3) Connective tissue breakdown products: 
Collegen-telopeptides, Osteocalcin, 
Proteoglycans, Breakdown products, Fibronectin 
fragments. 
4) Inflammatory mediators: Complement, 
Cytokines, Interleukins, Tumor necrosis factor-α, 
Interferon-α, Antibacterial Antibodies IgG, IgM, 
IgA, Substance P, Prostaglandin E2, Acute-phase 
proteins, transferrin, C-reactive protein. 
  
Also Specific salivary biomarkers for periodontal disease, 
which are considered to be the mirror of the body are 
enlisted below 
5 
(Table 1). 
All the enzymes released due to inflammatory process 
may or may not be truly associated with the disease 
activity. It is therefore very important to show that a 
potential marker has a true association with periodontal 
disease activity which is independent of and stronger 
than any association it may have with gingival 
inflammation. This is most clearly shown in comparisons 
of true and false positive and negative sites in respect of 
confirmed attachment loss which are used to compute 
the sensitivity, specificity and positive and negative 
predictive values of each markers. 
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                         Disease present  Disease Absent 
Test positive 
 
Test negative 
 
              
            Sensitivity =              Specificity =  
                   Positive predictive value =  
                  Negative predictive value =  
Thus if a reliable predictive test or test kits were 
developed it could predict future periodontal activity 
and thus enable site specific treatment to be given 
before irreversible damage had occurred. For this to be 
the case the marker, as already stated above, must have 
been shown in human longitudinal studies to have 
highly statistically significant correlations with confirmed 
attachment loss, both at the predictive and the 
attachment loss times. It should also have very high 
positive and negative predictive values in diagnostic 
values. 
Following are a few illustrations to understand it 
better; in patients who had clinical indicators of 
periodontitis salivary levels of TNFa were elevated
5
, 
Mean levels of IL-1b and MMP-8 in saliva were 
significantly higher than control subjects
5
. Thus MMP-8 
is not only an indicator of disease severity but also of  
disease activity
5
. The level of C-reactive protein; a 
systemic biomarker is directly related to an individual’s 
periodontal status
5
 which can be tested by lab-on-chip 
method
6
. Periodontitis-prone individuals are capable of 
secreting high levels of salivary IgA
5
. 
Only Biomarkers with such credentials should be 
used in clinical practice and could be used for the 
following reasons:- 
 Help to prevent destructive disease. 
 Help to prevent progression of disease. 
 Identify high risk patients. 
 Target treatment to specific sites. 
 Help to monitor periodontal treatment 
 
Henceforth; we move onto biomarkers of periodontal 
disease activity available as Commercial diagnostic tests 
and those under development.
7
 as enlisted below in 
Table. 2 
Proteomic 
Biomarkers 
Genetic 
Biomarkers 
Microbial  
Biomarkers 
Other  
biomarkers 
Cystatins, α-glucosidase, 
Acid phosphatise, 
Alkaline phosphatise, 
Aminopeptidase, 
Lactoferrin, Translactoferin, 
IgM,  MMP-13,  MMP-8, MMP-
9,  Cathepsin B, Osteonectin, 
Osteocalcin, Osteopontin, 
Osteopontin, Elastase Platelet-
activating factor,  
Epidermal growth factor, 
Platelet-derived growth factor, 
Esterase, 
Pyridinoline crosslinked 
carboxyterminal telopeptide, 
Fibronectin,sIgA (secretory IgA) 
Gelatinase, IgA, Trypsin, 
Vascular endothelial growth 
factor, IgG 
Cathepsin C gene Mutation, 
Collagen gene mutation, 
IL-1 polymorphisms, 
IL-10 polymorphisms, 
Tumor necrosis factor, 
Polymorphisms. 
Aggregatibacter 
Actinomycetemcomitans, 
Campylobacter rectus, 
Mycoplasmas,  
Porphyromonas 
Gingivalis, 
Prevotella intermedia, 
Peptostreptococcus 
Micros, 
 Prevotella nigrescens, 
Treponema denticola,  
Tannerella forsythia. 
Treponema socranskii.  
Calcium, 
Cortisol, 
Hydrogen sulphide, 
Methylmercaptan, 
Methylmercaptan, 
Methylmercaptan, 
Pyridine. 
A 
(True-positive) 
C 
(False-positive) 
B 
(False-negative) 
D 
(True-negative) 
Table. 1 Biomarkers For Periodontal Disease. 
 
Fig.1 Current and future diagnostic tools 
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A. a: Aggregatibacter actinomycetemcomitans, B. f: Bacteroides forsythus, C. r: Campylobacter rectus, E. c: Eikenella corrodens, P.m: Peptostreptococcus 
micros, P. g: Porphyromonas gingivalis, P. i: Prevotella intermedia, P. d: Prevotella denticola, T. d: Treponema denticola. 
 
Assay 
 
Kit Manufacturer/ 
supplier 
Avail
abilit
y 
                               Comments       
Reference
s 
Culture& 
biochemical 
Identification 
(GOLD 
STANDARD) 
Laboral 
 
 
 
Prognostik 
Laboral, France 
 
 
 
Dentsply 
Yes 
 
 
 
?? 
Quantification/identification after bacterial 
culture of A. a,B. f, C. r, F. n, P. i, P. g, P. M 
aids in detection of proteinase , elastase 
 
Immunological 
dection 
(ELISA 
Evaluisite test Kodak,Eastman 
company. 
(Switzerland) 
No Detects bacterial antigens of A.a, P. i, 
P. g. 
can be used at chairside. 
 
(8) 
Bacterial 
enzymes 
Perioscan 
 
BANA 
periodontal 
test 
Oral B laboratories 
OraTec Corporation 
Manassas (USA) 
No 
 
Yes 
Detects enzymatic activity of Aa, Bf, Pg 
detects enzymatic activity of B. f, P. g, T. d 
 
(9) 
Bacterial toxins TOPAS  Affinity Labeling 
Technologies (USA) 
Yes Detects toxins derived from anaerobic 
metabolism and measures GCF protein level. 
 
Host enzymes Periocheck Collagenex 
pharmaceuticals 
No Detects enzymatic activity derived from 
GCF(Matrixmetalloproteinases and 
neutral protease enzymes) 
 
 
(9) 
Nucleic.acid 
technology 
Affirm DP 
 
BTD test 
 
OMTL test, 
 
Omnigene 
 
 
Periodontal 
microbial 
identification 
test.                                                                  
ANAWA, 
DMDx
®
/ 
Pathotec
®
 
 
Parogene 
 
Explore 
 
 
 
IAI Pado test 
4.5 
Microdent
®
 
test 
 
 
MicroDent test 
kit 
Microprobe 
(USA) 
BioTechnicaDiagnostic
(USA) 
USC (USA) 
 
Omnigene(USA) 
 
 
Saigene corporation 
(USA) 
 
Switzerland 
 
 
 
France 
 
Explore 
(Netherlands) 
 
 
IAI(Switzerland) 
 
HAIN(Germany) & 
MicroDentex 
(USA) 
 
Szabo-scandic(Austria) 
?? 
 
?? 
 
Yes 
 
Yes 
 
 
?? 
 
 
Yes 
 
 
 
No 
 
Yes 
 
 
 
Yes 
 
Yes 
Yes 
 
 
Yes 
DNA probes for A. a, B. f, P. i,  P. g, T. D 
DNA probes for A.a, C.r, E.c, F.n, P.i, P.g. 
DNA probes for B. f, 
 P. g 
DNA probes for A. a, P.i,  P. g, E. c, F. n, 
T. d, C. r, B.f 
DNA probe for b.f, P.g 
 
 
DNA probes for A.a, P.g, P.i, E.c, B.f, C.r, T.d, 
F.n 
 
DNA probes for A.a, P.g, P.i, E.c, B.f, C.r 
rRNA quantification for P. g, A.a, B. f, 
T. d 
 
DNA probes for A.a, P.g, B.f, T.d. 
PCR detection for A.a, P.g, P.i, B.f, T.d 
 
 
Detection of A.a, P.g, P.i, P.d 
(10) 
 
 
 
 
 
(11) 
 
 
(12) 
 
 
 
 
 
 
 
 
 
 
(13) 
 
 
 
 
 
(14) 
Table. 2: Commercial diagnostic tests. 
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There are some advantages of these systems over 
conventional diagnosis since few may be capable of 
detecting or predicting periodontal disease activity. 
There are also, however, some serious drawbacks of all 
these tests described below. 
 
 
Advantages: 
 Some; for eg. cathepsin B, elastase etc.. are 
predictive of disease activity in longitudinal 
studies. 
 Simple to use, particularly the colour detection 
systems. 
 Can be read after a short time. 
 Can be shown to the patient and related to the 
tooth site. 
 
Disadvantages 
 The choice of the most appropriate biomarker 
may still be difficult at the present state of 
knowledge. 
 
 
 
 
 
 
 There is difficulty in determining the sites to 
sample and when to sample them. 
 They are not cost effective. 
 If a moiety is associated with inflammation this 
may mask its association with destructive 
disease. 
 
 
Critical Evaluation: 
 
All of the markers used in the commercially available 
test systems and those under development have been 
shown to be capable of detecting disease activity. 
However, only a few of the enzymes described above 
appear to be actively predictive of disease activity (Fig. 
2)(Chart 1). 
Therefore the evaluation of some of the recently 
used biomarkers and some under developmental stage 
are shown below in Table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic test Disease active sites Sites at Risk Response to treatment Tool for patient education 
DNA analysis       X     
Immunological assays       X           X 
Enzyme based assays       X     
GCF markers       ?     
Chart 1: Clinical Assesment Charting For Office Use 
 
Figure 2: Strategy for oral fluid sampling and analysis with a rapid point-of-care or lab-on-a-chip device for 
the generation of a periodontal disease biomarker report. 
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Sl 
no. 
 
  Assay. 
 
Diagnostic kit. 
 
 
           Critical Evaluation. 
1 Culture & 
biochemical 
Identification (GOLD 
STANDARD) 
Laboral It is highly technique sensitive & time consuming. 
But it can be used for testing against resistant pathogens. 
Pathogens of secondary importance can also reported if found in 
high percentage. 
2 Bacterial enzymes & 
host enzymes 
BANA(benzoyl-DL-
arginine-β-
napthylamide) 
 
 
 
 
 
 
 
 
Periocheck 
Perioscan 
 
Pathogens like T. d, B. f, P. g can be detected. With 90-96% 
sensitivity, 83-92% specificity. But A. a can’t be detected; using 
BANA. 
 
Clinical studies have shown the usefulness of BANA hydrolytic 
activity, the presence of which is significantly correlated with 
pocket probing depths and attachment loss greater than 4 mm. 
The number of BANA-positive sites observed in periodontitis 
patients decreases after successful therapy comprising scaling, 
root planing andadministration of systemic antibiotics. 
 
Both periocheck & perioscan were not very successful & some are 
no longer distributed. 
3 Immunological 
detection 
Evalusite Polyclonal & monoclonal antibodies are conjugated along with 
fluroscent reporters to enhance the specificity & sensitivity. Both 
are relatively low for this test. 
Therefore this commercial product is not widely marketed.  
4 Nucleic acid 
technology 
Genomic probe. 
Oligonucleotide 
probe. (CHUBA 
introduced them) 
 
Chemiluminesence 
generating  
Oligonucliotide 
probes 
 
 
DMDx/PATHOTEK 
 
 
IAI Pado Test 4.5 
System 
 
 
 
LCL
®
Periodontitis-Test 
 
 
P. i, P. g can be detected with the aid of purified DNA fragments, 
but the same way A. a could not be detected. 
Species such as P. i, P. g, & also A. a could be detected. Using 
radioactively labelled DNA probes. 
 
 
It is a laboratory procedure for demonstrating periodontopathic 
bacteria. 
 
Both IAI & LCL has been performing tests to check for its efficacy, 
& inclination towards it is rapidly growing in practitioners. 
5  Biochemical 
Identification  
Prognostik (Dentsply) 
 
 
 
 
 
Pocket watch 
 
 
Periogard ( Colgate) 
Helps in detection of elastase & protinease in GCF 
The commercial firms owning these tests are constantly changing 
because some of them sell the rights to their products to others.  
For this reason, the firms cited as owning these tests may not 
remain accurate in the future. 
 
Detects aspartate aminotransferase through colorimetric 
detection 
 
Detects AST levels in GCF through colorimetric detection. 
 
A. a: Aggregatibacter actinomycetemcomitans, B. f: Bacteroides forsythus, C. r: Campylobacter rectus, E. c: Eikenella corrodens, P.m: Peptostreptococcus 
micros, P. g: Porphyromonas gingivalis, P. i: Prevotella intermedia, P. d: Prevotella denticola, T. d: Treponema denticola. 
 
 Table 3. Available test kits and their evaluation. 
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Current Concepts & Future Trends: 
Therefore, now there is a whole new approach for the 
future use of oral fluids, especially in the field of 
diagnostics. A tremendous amount of research activity is 
currently under way to explore their role as a possible 
medium in a variety of applications. There are quite a 
few commercial diagnostic kits under practice such as β- 
glucuronidase: Abbott laboratories (U.S.A), 
dentoAnalyzer is among the first quantitative MMP-8 
chair-side testing devices in periodontal and peri-
implant diagnostics and research. Immunofluorometric 
assay and dento-analyzer can detect MMP-8 from GCF 
samples. Electrochemical biosensors coupled to 
Magnetic Beads are also used for the Detection of 
Clinical Biomarkers. Also several researchers have 
focused on genetic single nucleotide polymorphisms in 
the study of periodontitis.  There is a genetic 
susceptibility test currently available for severe chronic 
periodontitis (Interleukin Genetics, Waltham. 
Massachusetts).  Individuals identified as "genotype 
positive," are more likely to have the phenotype of 
overexpression of this gene. In this way genomics has 
been found to be applicable in the prediction of 
predisposition to periodontitis in certain patient 
populations. Moreover, technologies such as nucleic acid 
and protein microarrays and microfluidics are under 
development for risk assessment and comprehensive 
screening of biomarkers. These recent advances are 
leading to the development of more powerful diagnostic 
tools for practitioners to optimize their treatment 
predictability. 
 
Conclusion 
Thus, it can be concluded that though several 
products show potential benefit; which gives a clue as to 
which tissue components are at risk, most of the test kit, 
or biomarkers yield little or no additional information, at 
high costing. It is also clear that no single marker has 
been able to fulfil all the criteria necessary for 
assessment of the clinical state of the periodontium, and 
future research should be directed possibly at the 
production of "marker packages" As of now various 
efforts are on to develop an ideal test, but actual use as 
a chairside diagnostic is still illusive. Therefore the 
development of a wide spectrum of markers is the 
primary goal of periodontal research. 
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